Related Experiment Video

Updated: May 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Do statins cause diabetes?

Mark R Goldstein1, Luca Mascitelli

  • 1NCH Healthcare Group, 1845 Veterans Park Drive, Suite 110, Naples, FL 34109, USA. markrgoldstein@comcast.net

Current Diabetes Reports
|March 5, 2013
PubMed

Insights

Cholesterol-lowering statin drugs increase diabetes risk by affecting pancreatic beta cells and insulin sensitivity. Physicians can manage these risks, but long-term studies are needed to confirm cardiovascular benefits.

Area of Science:

  • Cardiovascular Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Statins are widely prescribed for cardiovascular disease prevention.
  • Evidence links statin use to an increased risk of new-onset diabetes.
  • Mechanisms may involve impaired pancreatic beta cell function and reduced insulin sensitivity.

Purpose of the Study:

  • To review the diabetogenic effects of statin therapy.
  • To identify populations at higher risk for statin-induced diabetes.
  • To discuss clinical strategies for mitigating adverse effects.

Main Methods:

  • Literature review of evidence on statins and diabetes risk.
  • Analysis of dose-dependency and cholesterol-lowering effects.
  • Discussion of hyperinsulinemia and its implications.

Main Results:

  • Statin therapy is associated with increased diabetes risk, particularly in the elderly, women, and Asians.
  • Risk correlates with statin dose and degree of cholesterol reduction.
  • Statins can induce hyperinsulinemia, even without hyperglycemia.

Conclusions:

  • Statin-induced diabetes is a significant concern, linked to impaired beta cell function and insulin sensitivity.
  • Clinical management should aim to mitigate hyperinsulinemic and diabetogenic effects.
  • Long-term studies are crucial to assess if cardiovascular benefits outweigh these metabolic risks.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...